Akebia Therapeutics
(AKBA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 66,712 | 76,248 | 27,887 | 32,780 | 49,668 |
| Marketable Securities | 90,754 | 76,541 | 72,446 | 76,138 | 68,670 |
| Receivables | 14 | 48 | 74 | N/A | 57 |
| TOTAL | $158,804 | $154,962 | $102,695 | $110,480 | $119,840 |
| Non-Current Assets | |||||
| PPE Net | 479 | 398 | 404 | 210 | 205 |
| Other Non-Current Assets | 305 | 305 | 360 | 305 | 125 |
| TOTAL | $784 | $703 | $764 | $515 | $330 |
| Total Assets | $159,588 | $155,665 | $103,459 | $110,995 | $120,170 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,273 | 2,412 | 4,329 | 2,021 | 3,032 |
| Accrued Expenses | 8,893 | 3,491 | 4,512 | 4,864 | 3,490 |
| TOTAL | $14,166 | $5,903 | $8,841 | $6,885 | $6,522 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 10 | 10 | 9 | 32 | 34 |
| TOTAL | $10 | $10 | $9 | $32 | $34 |
| Total Liabilities | $14,176 | $5,913 | $8,850 | $6,917 | $6,556 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 30,632 | 28,883 | 28,837 | 20,371 | 20,341 |
| Retained earnings | -141,532 | -122,057 | -111,368 | -100,673 | -90,303 |
| Other shareholders' equity | -169 | -189 | -169 | -218 | -131 |
| TOTAL | $145,412 | $149,752 | $94,609 | $104,078 | $113,614 |
| Total Liabilities And Equity | $159,588 | $155,665 | $103,459 | $110,995 | $120,170 |